AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease

AbbVie Inc. (NYSE:ABBV) is one of the best undervalued stocks to invest in right now.

AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn's Disease

AbbVie Inc. (NYSE:ABBV) announced on March 2 positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab subcutaneous induction treatment versus placebo in adult patients with moderately to severely active Crohn’s disease. The company reported that results from the study show notably higher proportions of patients treated with risankizumab SC induction attained the co-primary endpoints of Crohn’s Disease Activity Index clinical remission and endoscopic response at week 12 compared to placebo.

Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie Inc. (NYSE:ABBV), stated that the level of endoscopic response marks a particularly meaningful achievement for Crohn’s disease patients, and that these results highlight the company’s continued innovation and research to raise the standard of care.

The company further reported that during the 12-week, double-blind, placebo-controlled period, the safety profile of risankizumab SC remained consistent with the safety profile observed in Crohn’s disease, with no new safety risks observed. Upper respiratory tract infection, abdominal pain, and arthralgia were the most common adverse events observed among patients receiving risankizumab, and serious adverse events occurred in 0.5% of patients in the risankizumab SC group compared to 3.1% in the placebo group.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.